Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Defining the Hallmarks of Metastasis.

Welch DR, Hurst DR.

Cancer Res. 2019 Jun 15;79(12):3011-3027. doi: 10.1158/0008-5472.CAN-19-0458. Epub 2019 May 3. Review.

PMID:
31053634
2.

Anticipatory prefrontal cortex activity underlies stress-induced changes in Pavlovian fear conditioning.

Goodman AM, Harnett NG, Wheelock MD, Hurst DR, Orem TR, Gossett EW, Dunaway CA, Mrug S, Knight DC.

Neuroimage. 2018 Jul 1;174:237-247. doi: 10.1016/j.neuroimage.2018.03.030. Epub 2018 Mar 16.

3.

SIN3A and SIN3B differentially regulate breast cancer metastasis.

Lewis MJ, Liu J, Libby EF, Lee M, Crawford NP, Hurst DR.

Oncotarget. 2016 Nov 29;7(48):78713-78725. doi: 10.18632/oncotarget.12805.

4.

Breast Cancer Metastasis Suppressor 1 (BRMS1): Robust Biological and Pathological Data, But Still Enigmatic Mechanism of Action.

Welch DR, Manton CA, Hurst DR.

Adv Cancer Res. 2016;132:111-37. doi: 10.1016/bs.acr.2016.05.003. Epub 2016 Jun 17. Review.

PMID:
27613131
5.

Increased autophagic response in a population of metastatic breast cancer cells.

Li YI, Libby EF, Lewis MJ, Liu J, Shacka JJ, Hurst DR.

Oncol Lett. 2016 Jul;12(1):523-529. Epub 2016 May 24.

6.

Globular adiponectin enhances invasion in human breast cancer cells.

Falk Libby E, Liu J, Li YI, Lewis MJ, Demark-Wahnefried W, Hurst DR.

Oncol Lett. 2016 Jan;11(1):633-641. Epub 2015 Nov 24.

7.

SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.

Yu H, Liu Y, McFarland BC, Deshane JS, Hurst DR, Ponnazhagan S, Benveniste EN, Qin H.

Cancer Immunol Res. 2015 Jul;3(7):727-40. doi: 10.1158/2326-6066.CIR-15-0004. Epub 2015 Feb 3.

8.

Promising oncolytic agents for metastatic breast cancer treatment.

Cody JJ, Hurst DR.

Oncolytic Virother. 2015 Jun 3;4:63-73. doi: 10.2147/OV.S63045. eCollection 2015. Review.

9.

Linking adiponectin and autophagy in the regulation of breast cancer metastasis.

Libby EF, Frost AR, Demark-Wahnefried W, Hurst DR.

J Mol Med (Berl). 2014 Oct;92(10):1015-23. doi: 10.1007/s00109-014-1179-5. Epub 2014 Jun 7. Review.

10.

Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.

Cody JJ, Markert JM, Hurst DR.

PLoS One. 2014 Mar 20;9(3):e92919. doi: 10.1371/journal.pone.0092919. eCollection 2014.

11.

Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix.

Khotskaya YB, Beck BH, Hurst DR, Han Z, Xia W, Hung MC, Welch DR.

Mol Carcinog. 2014 Dec;53(12):1011-26. doi: 10.1002/mc.22068. Epub 2013 Sep 2.

12.

Mitochondrial bioenergetics of metastatic breast cancer cells in response to dynamic changes in oxygen tension: effects of HIF-1α.

Diers AR, Vayalil PK, Oliva CR, Griguer CE, Darley-Usmar V, Hurst DR, Welch DR, Landar A.

PLoS One. 2013 Jun 28;8(6):e68348. doi: 10.1371/journal.pone.0068348. Print 2013.

13.

Unraveling the 'TGF-β paradox' one metastamir at a time.

Welch DR, Hurst DR.

Breast Cancer Res. 2013 Feb 27;15(1):305. doi: 10.1186/bcr3383.

14.

The C-terminal putative nuclear localization sequence of breast cancer metastasis suppressor 1, BRMS1, is necessary for metastasis suppression.

Hurst DR, Xie Y, Thomas JW, Liu J, Edmonds MD, Stewart MD, Welch DR.

PLoS One. 2013;8(2):e55966. doi: 10.1371/journal.pone.0055966. Epub 2013 Feb 4.

15.

Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes.

Hurst DR.

Cancer Metastasis Rev. 2012 Dec;31(3-4):641-51. doi: 10.1007/s10555-012-9363-y. Review.

PMID:
22678236
16.

The influence of the cancer microenvironment on the process of metastasis.

Frost AR, Hurst DR, Shevde LA, Samant RS.

Int J Breast Cancer. 2012;2012:756257. doi: 10.1155/2012/756257. Epub 2012 Apr 18. No abstract available.

17.

Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis.

Cook LM, Cao X, Dowell AE, Debies MT, Edmonds MD, Beck BH, Kesterson RA, Desmond RA, Frost AR, Hurst DR, Welch DR.

Clin Exp Metastasis. 2012 Apr;29(4):315-25. doi: 10.1007/s10585-012-9452-x. Epub 2012 Jan 13.

18.

Clinical significance of KISS1 protein expression for brain invasion and metastasis.

Ulasov IV, Kaverina NV, Pytel P, Thaci B, Liu F, Hurst DR, Welch DR, Sattar HA, Olopade OI, Baryshnikov AY, Kadagidze ZG, Lesniak MS.

Cancer. 2012 Apr 15;118(8):2096-105. doi: 10.1002/cncr.26525. Epub 2011 Sep 16.

19.

Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression.

Hurst DR, Welch DR.

FEBS Lett. 2011 Oct 20;585(20):3185-90. doi: 10.1016/j.febslet.2011.07.045. Epub 2011 Aug 5. Review.

20.

Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.

Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD.

J Biol Chem. 2011 Sep 2;286(35):30377-83. doi: 10.1074/jbc.M111.254789. Epub 2011 Jul 11.

22.

Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines.

Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya KS, Welch DR, Frost AR.

Clin Exp Metastasis. 2011 Jun;28(5):437-49. doi: 10.1007/s10585-011-9382-z. Epub 2011 Mar 27.

23.

Metastasis suppressor genes at the interface between the environment and tumor cell growth.

Hurst DR, Welch DR.

Int Rev Cell Mol Biol. 2011;286:107-80. doi: 10.1016/B978-0-12-385859-7.00003-3. Review.

24.

Metastasis suppressors and the tumor microenvironment.

Cook LM, Hurst DR, Welch DR.

Semin Cancer Biol. 2011 Apr;21(2):113-22. doi: 10.1016/j.semcancer.2010.12.005. Epub 2010 Dec 17. Review.

25.

Metastamir: the field of metastasis-regulatory microRNA is spreading.

Hurst DR, Edmonds MD, Welch DR.

Cancer Res. 2009 Oct 1;69(19):7495-8. doi: 10.1158/0008-5472.CAN-09-2111. Epub 2009 Sep 22. Review.

26.

Linking metastasis suppression with metastamiR regulation.

Edmonds MD, Hurst DR, Welch DR.

Cell Cycle. 2009 Sep 1;8(17):2673-5. Epub 2009 Sep 23. No abstract available.

27.

Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression.

Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR.

Int J Cancer. 2009 Oct 15;125(8):1778-85. doi: 10.1002/ijc.24616.

28.

Nuclear magnetic resonance and circular dichroism study of metastin (Kisspeptin-54) structure in solution.

Shin R, Welch DR, Mishra VK, Nash KT, Hurst DR, Rama Krishna N.

Clin Exp Metastasis. 2009;26(6):527-33. doi: 10.1007/s10585-009-9252-0. Epub 2009 Mar 24.

29.

Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.

Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR.

Oncol Rep. 2009 Mar;21(3):761-7.

PMID:
19212637
30.

Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR.

Cancer Res. 2009 Feb 15;69(4):1279-83. doi: 10.1158/0008-5472.CAN-08-3559. Epub 2009 Feb 3.

31.

Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells.

Silveira AC, Hurst DR, Vaidya KS, Ayer DE, Welch DR.

Cancer Lett. 2009 Apr 8;276(1):32-7. doi: 10.1016/j.canlet.2008.10.024. Epub 2008 Dec 13.

32.

Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis.

Welch DR, Cooper CR, Hurst DR, Lynch CC, Martin MD, Vaidya KS, VanSaun MN, Mastro AM.

Cancer Res. 2008 Dec 1;68(23):9578-82. doi: 10.1158/0008-5472.CAN-08-3360. No abstract available.

33.

Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model.

Hurst DR, Xie Y, Edmonds MD, Welch DR.

Clin Exp Metastasis. 2009;26(2):89-96. doi: 10.1007/s10585-008-9216-9. Epub 2008 Oct 8.

34.

Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling.

Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG, Casey G, DeWald DB, Welch DR.

J Biol Chem. 2008 Oct 17;283(42):28354-60. doi: 10.1074/jbc.M710068200. Epub 2008 Jul 29.

35.

BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process.

Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR.

Am J Pathol. 2008 Mar;172(3):809-17. doi: 10.2353/ajpath.2008.070772. Epub 2008 Feb 14.

36.

Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells.

Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR.

J Biol Chem. 2008 Mar 21;283(12):7438-44. doi: 10.1074/jbc.M709446200. Epub 2008 Jan 22.

37.

A MSC-ing link in metastasis?

Hurst DR, Welch DR.

Nat Med. 2007 Nov;13(11):1289-91. No abstract available.

38.

Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy.

Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JC, Peiper SC, Welch DR.

J Natl Cancer Inst. 2007 Feb 21;99(4):309-21. Erratum in: J Natl Cancer Inst. 2007 Jul 20;99(12):977.

39.

Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone.

Hurst DR, Mehta A, Moore BP, Phadke PA, Meehan WJ, Accavitti MA, Shevde LA, Hopper JE, Xie Y, Welch DR, Samant RS.

Biochem Biophys Res Commun. 2006 Oct 6;348(4):1429-35. Epub 2006 Aug 10.

40.

Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases.

Sang QX, Jin Y, Newcomer RG, Monroe SC, Fang X, Hurst DR, Lee S, Cao Q, Schwartz MA.

Curr Top Med Chem. 2006;6(4):289-316. Review.

PMID:
16611144
41.
42.

Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1).

Samant RS, Debies MT, Hurst DR, Moore BP, Shevde LA, Welch DR.

Cancer Lett. 2006 Apr 28;235(2):260-5. Epub 2005 Jun 22.

PMID:
15978719
43.

A video database of moving faces and people.

O'Toole AJ, Harms J, Snow SL, Hurst DR, Pappas MR, Ayyad JH, Abdi H.

IEEE Trans Pattern Anal Mach Intell. 2005 May;27(5):812-6.

PMID:
15875802
44.

Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities.

Hurst DR, Schwartz MA, Ghaffari MA, Jin Y, Tschesche H, Fields GB, Sang QX.

Biochem J. 2004 Feb 1;377(Pt 3):775-9.

45.

The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.

Park HI, Jin Y, Hurst DR, Monroe CA, Lee S, Schwartz MA, Sang QX.

J Biol Chem. 2003 Dec 19;278(51):51646-53. Epub 2003 Oct 7.

46.

Protein engineering and properties of human metalloproteinase and thrombospondin 1.

Wei P, Zhao YG, Zhuang L, Hurst DR, Ruben S, Sang QX.

Biochem Biophys Res Commun. 2002 Apr 26;293(1):478-88.

PMID:
12054626
47.

Diagnosis and endovascular treatment of iliocaval compression syndrome.

Hurst DR, Forauer AR, Bloom JR, Greenfield LJ, Wakefield TW, Williams DM.

J Vasc Surg. 2001 Jul;34(1):106-13.

48.

Development and characterization of a new polyclonal antibody specifically against tissue inhibitor of metalloproteinases 4 in human breast cancer.

Hurst DR, Li H, Xu X, Badisa VL, Shi YE, Sang QX.

Biochem Biophys Res Commun. 2001 Feb 16;281(1):166-71.

PMID:
11178975
49.

Diagnosis of pulmonary embolism: comparison of CT angiography and MR angiography in canines.

Hurst DR, Kazerooni EA, Stafford-Johnson D, Williams DM, Platt JF, Cascade PN, Prince MR.

J Vasc Interv Radiol. 1999 Mar;10(3):309-18.

PMID:
10102196
50.

Magnetic resonance angiography with gadomer-17. An animal study original investigation.

Dong Q, Hurst DR, Weinmann HJ, Chenevert TL, Londy FJ, Prince MR.

Invest Radiol. 1998 Sep;33(9):699-708.

PMID:
9766055

Supplemental Content

Loading ...
Support Center